These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25555173)

  • 1. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy.
    Thanathanee O; Sriphon P; Anutarapongpan O; Athikulwongse R; Thongphiew P; Rangsin R; Suwan-apichon O
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):165-8. PubMed ID: 25555173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
    Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
    Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO; Feng MT; Scanameo A; Price FW
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis.
    White EM; Macy JI; Bateman KM; Comstock TL
    Curr Med Res Opin; 2008 Jan; 24(1):287-96. PubMed ID: 18062846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ; Djalilian AR; Sanderson JP
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper.
    Mifflin MD; Betts BS; Frederick PA; Feuerman JM; Fenzl CR; Moshirfar M; Zaugg B
    Clin Ophthalmol; 2017; 11():1113-1118. PubMed ID: 28652697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized prospective clinical trial comparing laser subepithelial keratomileusis and photorefractive keratectomy.
    Pirouzian A; Thornton JA; Ngo S
    Arch Ophthalmol; 2004 Jan; 122(1):11-6. PubMed ID: 14718288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Efficacy and Safety of Loteprednol Etabonate 0.5% and Topical Dexamethasone 1% in Post-Vitrectomy Inflammation.
    Bilgin AB; Dogan ME; Ayaz Y; Apaydin KC
    Ocul Immunol Inflamm; 2019; 27(2):312-318. PubMed ID: 29283786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial healing and clinical outcomes in excimer laser photorefractive surgery following three epithelial removal techniques: mechanical, alcohol, and excimer laser.
    Lee HK; Lee KS; Kim JK; Kim HC; Seo KR; Kim EK
    Am J Ophthalmol; 2005 Jan; 139(1):56-63. PubMed ID: 15652828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R; Horwitz B; Howes J; Novack GD; Hart K
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD; Howes J; Crockett RS; Sherwood MB
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of basic fibroblast growth factor on corneal epithelial healing after photorefractive keratectomy.
    Meduri A; Aragona P; Grenga PL; Roszkowska AM
    J Refract Surg; 2012 Mar; 28(3):220-3. PubMed ID: 22230058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2.
    Ophthalmology; 1998 Sep; 105(9):1780-6. PubMed ID: 9754192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of early postoperative clinical outcomes of photorefractive keratectomy and lamellar epithelial debridement.
    Youm DJ; Tchah H; Choi CY
    J Cataract Refract Surg; 2009 Apr; 35(4):703-9. PubMed ID: 19304092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children.
    Yoo YJ; Yang HK; Hwang JM
    J Ocul Pharmacol Ther; 2018; 34(6):468-476. PubMed ID: 29958057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of topical treatment on epithelial wound healing and pain in the early postoperative period following photorefractive keratectomy.
    Tomas-Barberan S; Fagerholm P
    Acta Ophthalmol Scand; 1999 Apr; 77(2):135-8. PubMed ID: 10321525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis.
    Rhee SS; Mah FS
    Adv Ther; 2007; 24(1):60-7. PubMed ID: 17526462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery.
    Salinger CL; Gordon M; Jackson MA; Perl T; Donnenfeld E
    Clin Ophthalmol; 2015; 9():2089-97. PubMed ID: 26609219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.